Table 1.

STRESS-L schedule of interventions

Procedure (time (T) in days/hours)	Screening (T0–12)	Baseline (day 0–24 hours—T0)	Day 1 (T0+24)	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9	Day 10	Day 11	Day 12	Day 13	Day 14	EONT visit	FU visit day 28	Final visit day 90
Eligibility assessment	●
Informed consent		●
Randomisation		●
Demographics		●
Medical history		●
ECG		●	According to clinical need or if adverse event (AE)/serious AE (SAE)
Pregnancy test		●
IMP		Dispense														End
Blood sample		●	●	●		●		●									●
Biobank blood sample (optional)		●	●														●
Transport of stored serum																	Batch
Local laboratory tests (normal clinical care):		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
C reactive protein		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Glucose		●	●	●		●		●									●
Lactate		●	●	●		●		●									●
Worst PaO2/FiO2		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Platelets		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Creatinine		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Bilirubin		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
White cell count		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Liver function tests (ALT or AST)		●	●	●		●		●									●
Central venous blood gas (BG)/ arterial BG		●	●	●		●		●									●
Microbiology results from local lab		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Heart rate (hourly: T0+7 days)		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Atrial fibrillation (hourly: T0+7 days)		●	●	●	●	●	●
Blood pressure (hourly: T0+7 days)		●	●	●	●	●	●
Rate of vasopressor/inotropes		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
In/out fluids		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
SOFA score		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
AEs (SAEs up to day 90)		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Steroid use		●	●	●		●		●									●
Compliance		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Mortality status																		●	●
End of trial																			●

ALT, alanine aminotransferase; AST, aspartate aminotransferase; EONT, end of norepinephrine treatment; FiO₂, fractional inspired oxygen; FU, follow-up; IMP, investigational medicinal product; PAO₂, arterial oxygen tension; SOFA, Sequential Organ Failure Assessment.